| abstract |
The invention provides a pharmaceutical formulation, which comprises a pre-release portion containing HMG-CoA (hydroxymethylglutaryl-CoA) reductase as a pharmacologically active component, and a sustained-release portion containing bis-dihydropyridine-class calcium-channel blocker as a pharmacologically active component. The formulation of the invention offers synergy effects through co-administration of the bis-dihydropyridine-class calcium-channel blocker/HMG-CoA (hydroxymethylglutaryl-CoA) reductase, and induces the time-dependent absorption, metabolism and mechanism of individual drug through the controlled release to avoid competitive antagonistic interactions between drugs, thus maximizing effects of each pharmacologically active component while minimizing side effects, for example, the risk of myopathy, and substantially increasing the compliance of patients by taking one tablet once per day. |